Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations.
In patients with chronic myeloid leukemia, the use of real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for measuring BCR-ABL1 transcripts has become standard methodology for the diagnosis and monitoring of minimal residual disease. In 2004 and 2005, 38 different laboratories from North America participated in three separate sample exchanges using real-time qRT-PCR to measure RNA transcript levels in unknown diluents of a BCR-ABL1-positive cell line, K562. In this study we compared results of quantitative testing for BCR-ABL1 from laboratories using different platforms, internal controls, reagents, and calculation methods. Our data showed that there can be considerable variability of results from laboratory to laboratory, with log reduction calculations varying from 1.6 to 3 log between laboratories at the same dilution. We found that none of the variables tested had a significant impact on the results reported, except for the use of ABL1 as the internal control (P < 0.001). Laboratories that used ABL1 consistently underreported their log reduction values. Regardless of the specific methodology and platform used for real-time qRT-PCR testing, it is important for laboratories to participate in proficiency testing to ensure consistent and acceptable test accuracy and sensitivity. Our study emphasizes the need for optimization of real-time qRT-PCR before offering clinical testing and the need for widely available universal standards that can be used for test calibration.
Zhang
Tong
T
Department of Pathology, The University Health Network, Toronto, Ontario, Canada.
Grenier
Sylvie
S
Nwachukwu
Bevoline
B
Wei
Cuihong
C
Lipton
Jeffrey H
JH
Kamel-Reid
Suzanne
S
D002138:Calibration; D018076:DNA, Complementary / Q000032:analysis / Q000235:genetics; D006801:Humans; D020014:K562 Cells; D007755:Laboratories, Hospital; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics; D009656:North America; D016133:Polymerase Chain Reaction / Q000592:standards*; D012334:RNA, Neoplasm / Q000235:genetics; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D020298:U937 Cells
D018076:DNA, Complementary; D012334:RNA, Neoplasm
Leukemia. 2000 Feb;14(2):324-8
10673752
Science. 1990 Mar 2;247(4946):1079-82
2408149
Nature. 1973 Jun 1;243(5405):290-3
4126434
Blood. 1992 Dec 15;80(12):2983-90
1467514
Leukemia. 2006 Nov;20(11):1925-30
16990771
Leukemia. 1999 Nov;13(11):1825-32
10557058
Leukemia. 2003 Dec;17(12):2318-57
14562125
Clin Chem. 1981 Mar;27(3):493-501
7471403
Clin Chem. 2004 May;50(5):846-56
15010424
Leukemia. 2003 Dec;17(12):2401-9
14523461
Br J Haematol. 2003 Mar;120(6):990-9
12648069
Blood. 1975 Mar;45(3):321-34
163658
Leuk Res. 2007 Apr;31(4):483-91
16945414
Blood. 2006 Jul 1;108(1):28-37
16522812
N Engl J Med. 2003 Oct 9;349(15):1423-32
14534335
Diagn Mol Pathol. 2006 Mar;15(1):56-61
16531770
Nature. 1985 Jun 13-19;315(6020):550-4
2989692
Methods Mol Med. 2006;125:69-92
16502578
Leukemia. 2005 Feb;19(2):305-7
15618967
Leukemia. 2003 Dec;17(12):2474-86
14562124
N Engl J Med. 2006 Dec 7;355(23):2408-17
17151364
Leukemia. 2002 Jan;16(1):53-9
11840263
Blood Rev. 2006 Jan;20(1):29-41
16426942
Br J Haematol. 1998 Aug;102(3):768-74
9722305
Leukemia. 1996 May;10(5):751-6
8656667
Curr Oncol. 2006 Dec;13(6):201-21
22792021
Leukemia. 2002 Sep;16(9):1579-83
12200666
Cancer Res. 1999 Jul 1;59(13):3171-4
10397261
Clin Chem. 2004 Jun;50(6):1088-92
15161732